Milestone Pharmaceuticals Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

MIST$0.66-10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Loss

Condensed Consolidated Statements of Loss** (Unaudited)**

(in thousands of US dollars, except share and per share data)


· · · · ·
· · Three months ended June 30, · · Six months ended June 30, ·
· 2025 · 2024 · 2025 · 2024 ·

Revenue	$—	$—	$—	$—

Operating expenses
Research and development, net of tax credits	3,669	2,815	8,647	6,454
General and administrative	3,759	5,046	8,926	8,999
Commercial	5,103	1,801	15,481	4,685

Loss from operations	(12,531)	(9,662)	(33,054)	(20,138)

Interest income	516	1,186	1,213	2,180
Interest expense	(951)	(887)	(1,886)	(1,759)

Net loss and comprehensive loss	$(12,966)	$(9,363)	$(33,727)	$(19,717)

Weighted average number of shares and pre-funded warrants outstanding, basic and diluted	66,380,118	66,165,461	66,333,024	58,160,286

Net loss per share, basic and diluted	$(0.20)	$(0.14)	$(0.51)	$(0.34)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.